Introduction

There is an increasing body of evidence surrounding the importance of a T cell-mediated response to SARS-CoV-2 infection and after COVID-19 vaccination. In this internal feasibility study, we evaluated both the total antibody (IgA, IgM, and IgG) and T cell responses in a cohort of COVID-19 convalescents and vaccinated individuals.

Methods

Whole blood specimens were collected weekly from 12 subjects at different time points within/after the COVID-19 mRNA vaccination regimen, and from 4 PCR-confirmed convalescent donors to measure durability of humoral and cell-mediated immune response. T cell and antibody responses were evaluated via the QuantiFERON SARS-CoV-2 research use only (QFN SARS-CoV-2) assay which is an interferon gamma release assay (IGRA) and QIAreach Anti-SARS-CoV-2 total (Anti-CoV-2) test, respectively.

Results

In a cohort of recently vaccinated individuals, subjects demonstrated robust total antibody and CD4+/CD8+ T cell response to SARS-CoV-2 mRNA vaccines when followed for 2 months post-2nd dose. In most individuals, T cell response declined between the 1st and 2nd doses suggesting a need for a booster or the completion of the 2-dose vaccine series. In a group of convalescent donors tested with QFN SARS-CoV-2 and Anti-CoV-2 tests, all patients had an antibody and T cell response up to 1 year after natural infection.

Conclusion

This small feasibility study demonstrates that the QFN-SARS-CoV-2 test is able to identify CD4+ and CD8+ T cell-mediated responses in SARS-CoV-2-vaccinated subjects and those recovered from COVID-19, alongside a qualitative antibody response detectable via the QIAreach Anti-CoV2 test.

中文翻译：

---

QuantiFERON SARS-CoV-2 和 QIAreach 抗 SARS-CoV-2 总体检测在最近接种疫苗的个体中的初步评估

介绍

越来越多的证据表明，T 细胞介导的反应对 SARS-CoV-2 感染和 COVID-19 疫苗接种后的重要性。在这项内部可行性研究中，我们评估了一组 COVID-19 康复者和已接种疫苗的个体的总抗体（IgA、IgM 和 IgG）和 T 细胞反应。

方法

每周在 COVID-19 mRNA 疫苗接种方案内/之后的不同时间点从 12 名受试者以及 4 名 PCR 确认的恢复期供者身上采集全血样本，以测量体液和细胞介导的免疫反应的持久性。T 细胞和抗体反应通过 QuantiFERON SARS-CoV-2 研究专用 (QFN SARS-CoV-2) 检测（一种干扰素伽马释放检测 (IGRA)）和 QIAreach 抗 SARS-CoV-2 总检测（抗CoV-2）分别进行测试。

结果

在一组最近接种疫苗的个体中，受试者在第二次接种后 2 个月内表现出对 SARS-CoV-2 mRNA 疫苗的强大总抗体和 CD4+/CD8+ T 细胞反应。在大多数个体中，T 细胞反应在第 1 剂和第 2 剂之间下降，表明需要加强疫苗或完成 2 剂疫苗系列。在一组接受 QFN SARS-CoV-2 和抗 CoV-2 测试的康复期捐献者中，所有患者在自然感染后长达 1 年内都出现了抗体和 T 细胞反应。

结论

这项小型可行性研究表明，QFN-SARS-CoV-2 测试能够识别 SARS-CoV-2 疫苗接种受试者和从 COVID-19 恢复的受试者中 CD4+ 和 CD8+ T 细胞介导的反应，以及可检测的定性抗体反应通过 QIAreach 抗 CoV2 测试。